RecruitingPhase 3NCT07201129
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Studying Autosomal systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Viatris Innovation GmbH
- Principal Investigator
- Clinical TrialsViatris Innovation GmbH
- Intervention
- Cenerimod(drug)
- Enrollment
- 300 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2026 – 2030
Study locations (9)
- Alloy Clinical Research LLC, Kissimmee, Florida, United States
- SouthCoast Research Center, Miami, Florida, United States
- Allied Biomedical Research Institute, Miami, Florida, United States
- DH NationalResearchCenters INC, Miami, Florida, United States
- ProfessionalResearchCenter INC, Miami, Florida, United States
- San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States
- Rheumatology Care Center, PLLC, Bellaire, Texas, United States
- Novel Research, LLC., Houston, Texas, United States
- Northwest Houston Arthritis, Houston, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07201129 on ClinicalTrials.govOther trials for Autosomal systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07447986To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus ErythematosusHangzhou Sumgen Biotech Co., Ltd.
- RECRUITINGPHASE1NCT07363590A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07276958A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)Eli Lilly and Company
- RECRUITINGPHASE1, PHASE2NCT07348055A Study of GR1803 in Systemic Lupus ErythematosusGenrix (Shanghai) Biopharmaceutical Co., Ltd.
- RECRUITINGNCT07000110Anifrolumab Malignancy and Serious Infections StudyAstraZeneca
- RECRUITINGPHASE1NCT07318259Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGPHASE1NCT07331467Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLEChongqing Precision Biotech Co., Ltd
- RECRUITINGNCT07175285A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 ImmunosuppressantsBristol-Myers Squibb